Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Mar 22, 2017 (10 years ago)

Pilocarpine Hydrochloride Ophthalmic Solution 4%

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Pilocarpine Hydrochloride Ophthalmic Solution 4% , packaged in 15 mL bottles, Rx Only, Manufactured by Alcon Laboratories, Inc. Fort Worth, Texas 76134 Sandoz Princeton, NJ 08540, NDC 61314-206-15

Affected NDC 61314-0206-15

Compare with the code on your package — it is the most precise check available.

Drug: Pilocarpine Category: Eye Drops & Ophthalmic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Pilocarpine Hydrochloride
NDC 61314-0206
40 mg/mL Solution/ Drops
Ophthalmic
Sandoz Inc Rx
Recalling firm
Novartis Pharmaceuticals Corp.
NDC code
61314-206-15
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0679-2017 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Pilocarpine recalls

See all
Class III · Low risk

Isopto Carpine

Failed Impurities/Degradation Specifications.

Terminated Impurity / degradation Novartis Pharmaceuticals Corp. NDC 0998-0206-15 D-0678-2017

Other recalls by Novartis Pharmaceuticals Corp.

All 2017 recalls
Class II · Moderate risk

Diovan (valsartan)

Failed Dissolution Specifications

Ongoing Dissolution failure Novartis Pharmaceuticals Corporation NDC 0078-0359-34 D-0746-2026
Class I · High risk

SANDIMMUNE Oral Solution

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals

Ongoing Failed specification Novartis Pharmaceuticals Corporation NDC 0078-0110-22 D-0144-2024
Class I · High risk

SANDIMMUNE Oral Solution

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals.

Ongoing Failed specification Novartis Pharmaceuticals Corp. NDC 0078-0110-22 D-1174-2023
Class II · Moderate risk

Neoral soft gelatin capsules

CGMP deviations: Out of specification results obtained during routine stability testing for ethanol content.

Terminated Stability / shelf life Novartis Pharmaceuticals Corporation NDC 0078-0246-15 D-1543-2022